Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
Journal
Hepatology international
Journal Volume
16
Journal Issue
5
Pages
1199
Date Issued
2022-10
Author(s)
Chen, Ching-Tso
Feng, Yin-Hsun
Yen, Chia-Jui
Chen, San-Chi
Lin, Yun-Tzu
Abstract
The combination of atezolizumab and bevacizumab (Atezo-Bev) has become the standard first-line therapy for patients with advanced hepatocellular carcinoma (HCC), but the prognosis and treatment pattern after its treatment failure are unclear.
Subjects
Albumin-Bilirubin (ALBI) grade; Cancer of the Liver Italian Program (CLIP) score; Child–Pugh classification; Failure of Atezo-Bev treatment; Hepatocellular carcinoma; Liver function reserve; Prognosis; Second-line therapy; Systemic therapy; Treatment pattern
SDGs
Publisher
SPRINGER
Type
review